NASDAQ:ACOG Alpha Cognition Q3 2026 Earnings Date & Estimates $8.53 +0.33 (+4.02%) Closing price 11/4/2026 04:00 PM EasternExtended Trading$8.70 +0.17 (+1.99%) As of 11/4/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Alpha Cognition is scheduled to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Alpha Cognition in Q3 2026Alpha Cognition is expected to post earnings of -$0.33 per share on revenue of $7.04 million. In the same quarter a year earlier Alpha Cognition reported -$0.30 per share on revenue of $2.84 million. Alpha Cognition last reported on August 13, 2026, posting -$0.40 per share and missing the -$0.3921 consensus estimate. Alpha Cognition has beaten the consensus EPS estimate in 3 of its last 7 quarters.Consensus EstimatesConsensus EPS-$0.33Expected Revenue$7.04 millionPrior-Year EPS-$0.30Prior-Year Revenue$2.84 millionExpected Revenue Growth+147.8%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.40 (Missed by -$0.0079)Last Quarter Revenue$6 millionEPS Beat Rate3 of last 7 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Alpha Cognition Q3 2026 Earnings FAQ When does Alpha Cognition report Q3 2026 earnings? Alpha Cognition (NASDAQ:ACOG) has confirmed it will report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. What time is Alpha Cognition's Q3 2026 earnings call? Alpha Cognition's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Alpha Cognition? Analysts expect Alpha Cognition to post earnings of -$0.33 per share for Q3 2026. How much revenue is Alpha Cognition expected to report? The consensus revenue estimate for Alpha Cognition is $7.04 million for Q3 2026. Alpha Cognition Earnings HeadlinesAlpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business UpdateNovember 2 at 4:05 PM | businesswire.comAlpha Cognition Inc. (ACOG) - What Are Brokerages Saying About This Stock?November 2 at 3:16 AM | americanbankingnews.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th. | Behind the Markets (Ad)Analysts Offer Insights on Healthcare Companies: Alpha Cognition Inc (ACOG) and Travere Therapeutics (TVTX)October 3, 2026 | theglobeandmail.comAlpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | financialpost.comFAlpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | businesswire.comSee More Alpha Cognition Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Cognition? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Cognition and other key companies, straight to your email. Email Address About Alpha CognitionAlpha Cognition (NASDAQ:ACOG) is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative diseases and cognitive disorders. The company’s work is centered on therapies intended to address the medical needs of patients with Alzheimer’s disease and other conditions affecting cognition. Its lead commercial product is ZUNOVO (galantamine hydrobromide) extended-release capsules, an orally administered treatment approved by the U.S. Food and Drug Administration for mild-to-moderate dementia of the Alzheimer’s type. ZUNOVO is designed to provide an alternative formulation of galantamine for patients and caregivers managing Alzheimer’s disease treatment. Alpha Cognition is headquartered in Vancouver, British Columbia, and its principal commercial and regulatory activities are focused on the United States. In addition to ZUNOVO, the company has pursued a pipeline of investigational therapies for neurodegenerative and cognitive disorders. Its leadership team includes Chief Executive Officer Michael McFadden.View Alpha Cognition ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it SimpleEnergy Transfer's Earnings Miss May Be Hiding Its Strongest Advantage Upcoming Earnings Enbridge (11/6/2026)Brookfield Asset Management (11/6/2026)Humana (11/6/2026)Moderna (11/6/2026)Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
